Real-World, Observational Study Assessing The Proportion Of Leukapheresed Patients with Relapsed and Refractory Multiple Myeloma That Receive Infusion of Idecabtagene Vicleucel (CA089-1097)

Study identification

• EU PAS number:
  EUPAS1000000456
• Study ID:
  1000000456
• Official title and acronym:
  Real-World, Observational Study Assessing The Proportion Of Leukapheresed Patients with Relapsed and Refractory Multiple Myeloma That Receive Infusion of Idecabtagene Vicleucel (CA089-1097)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Switzerland

  United States
• Study status:
  Planned

Research institutions and networks

Institutions

Bristol-Myers Squibb (BMS)

Study timelines

Date when funding contract was signed

Actual: 05/08/2024

Study start date

Planned: 30/06/2025

Date of final study report

Planned: 30/09/2029

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable